JP6928005B2 - 新規なピペリジニル誘導体、それらの調製方法及びそれらを含有する医薬組成物 - Google Patents

新規なピペリジニル誘導体、それらの調製方法及びそれらを含有する医薬組成物 Download PDF

Info

Publication number
JP6928005B2
JP6928005B2 JP2018564356A JP2018564356A JP6928005B2 JP 6928005 B2 JP6928005 B2 JP 6928005B2 JP 2018564356 A JP2018564356 A JP 2018564356A JP 2018564356 A JP2018564356 A JP 2018564356A JP 6928005 B2 JP6928005 B2 JP 6928005B2
Authority
JP
Japan
Prior art keywords
methyl
carbonyl
pyrrolo
hydroxy
piperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018564356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517556A (ja
Inventor
コッチャイ,アンドラーシュ
ヴェーバー,チャバ
ヴァシャシュ,アティッラ
モルナール,バラージュ
キッシュ,アールパード
マシアス,アルバ
マレー,ジェームズ・ブルック
レフコヴィチ,エロディ
ジェネステ,オリヴィエ
シャンリオン,マイア
ドゥマール,ディディエ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vernalis R&D Ltd
Original Assignee
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis R&D Ltd filed Critical Vernalis R&D Ltd
Publication of JP2019517556A publication Critical patent/JP2019517556A/ja
Application granted granted Critical
Publication of JP6928005B2 publication Critical patent/JP6928005B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2018564356A 2016-06-10 2017-06-09 新規なピペリジニル誘導体、それらの調製方法及びそれらを含有する医薬組成物 Active JP6928005B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1655392A FR3052452B1 (fr) 2016-06-10 2016-06-10 Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR1655392 2016-06-10
PCT/EP2017/064067 WO2017212012A1 (en) 2016-06-10 2017-06-09 New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
JP2019517556A JP2019517556A (ja) 2019-06-24
JP6928005B2 true JP6928005B2 (ja) 2021-09-01

Family

ID=56943687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564356A Active JP6928005B2 (ja) 2016-06-10 2017-06-09 新規なピペリジニル誘導体、それらの調製方法及びそれらを含有する医薬組成物

Country Status (46)

Country Link
US (1) US11046681B2 (enExample)
EP (1) EP3468974B1 (enExample)
JP (1) JP6928005B2 (enExample)
KR (1) KR20190016106A (enExample)
CN (1) CN109311888B (enExample)
AR (1) AR108706A1 (enExample)
AU (1) AU2017277734B2 (enExample)
BR (1) BR112018075433A2 (enExample)
CA (1) CA3027014C (enExample)
CL (1) CL2018003474A1 (enExample)
CO (1) CO2018013210A2 (enExample)
CR (1) CR20180564A (enExample)
CU (1) CU20180145A7 (enExample)
CY (1) CY1122870T1 (enExample)
DK (1) DK3468974T3 (enExample)
DO (1) DOP2018000270A (enExample)
EA (1) EA037211B1 (enExample)
EC (1) ECSP18090144A (enExample)
ES (1) ES2775789T3 (enExample)
FR (1) FR3052452B1 (enExample)
GE (1) GEP20207160B (enExample)
HR (1) HRP20200361T1 (enExample)
HU (1) HUE049507T2 (enExample)
IL (1) IL263463B (enExample)
LT (1) LT3468974T (enExample)
MA (1) MA45222B1 (enExample)
MD (1) MD3468974T2 (enExample)
ME (1) ME03670B (enExample)
MX (1) MX374794B (enExample)
MY (1) MY196562A (enExample)
NI (1) NI201800132A (enExample)
NZ (1) NZ748946A (enExample)
PE (1) PE20220567A1 (enExample)
PH (1) PH12018502515B1 (enExample)
PL (1) PL3468974T3 (enExample)
PT (1) PT3468974T (enExample)
RS (1) RS60029B1 (enExample)
RU (1) RU2743163C2 (enExample)
SG (1) SG11201810629QA (enExample)
SI (1) SI3468974T1 (enExample)
SV (1) SV2018005791A (enExample)
TN (1) TN2018000410A1 (enExample)
TW (1) TWI620750B (enExample)
UA (1) UA123794C2 (enExample)
UY (1) UY37288A (enExample)
WO (1) WO2017212012A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021504388A (ja) * 2017-11-29 2021-02-15 レ ラボラトワール セルヴィエ ユビキチン特異的プロテアーゼ7の阻害剤としての新規ピペリジニル誘導体

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069488B (zh) 2016-03-07 2021-09-07 英安塔制药有限公司 乙型肝炎抗病毒剂
CA3060416A1 (en) 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
TWI811236B (zh) 2017-08-28 2023-08-11 美商因那塔製藥公司 B型肝炎抗病毒試劑
GB201801562D0 (en) * 2018-01-31 2018-03-14 Almac Diagnostics Ltd Pharmaceutical compounds
UY38291A (es) * 2018-07-05 2020-06-30 Servier Lab Nuevos derivados de amino-pirimidonilo un proceso para su preparación y composiciones farmacéuticas
US10865211B2 (en) 2018-09-21 2020-12-15 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
UY38423A (es) * 2018-10-19 2021-02-26 Servier Lab Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
BR112021010644A2 (pt) * 2018-12-06 2021-09-28 Almac Discovery Limited Composto, estereoisômero, tautômero, hidrato, derivado de n-óxido ou sal farmaceuticamente aceitável, composição farmacêutica, métodos para tratamento de obesidade, resistência a insulina, diabetes tipo ii, atrofia muscular e câncer e para redução de perda de massa muscular em um indivíduo, e, inibidor de usp19
US11236111B2 (en) 2019-06-03 2022-02-01 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
CN113087718B (zh) * 2020-01-09 2024-02-09 四川科伦博泰生物医药股份有限公司 噻吩并嘧啶酮类化合物及其医药应用
CN112608320B (zh) * 2020-01-16 2023-03-17 中国药科大学 哌啶类化合物及其制备方法和医药用途
GB202001980D0 (en) 2020-02-13 2020-04-01 Almac Discovery Ltd Therapeutic mentods
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2634235A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an h3 antagonist/inverse agonist and an appetite suppressant
EP2136805A2 (en) * 2007-03-02 2009-12-30 Schering Corporation Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
AR103297A1 (es) * 2014-12-30 2017-05-03 Forma Therapeutics Inc Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
MD3468971T2 (ro) * 2016-06-10 2020-06-30 Servier Lab Noi derivați de piperidinil (hetero)aril-substituiţi, procedeu de obţinere a acestora și compoziții farmaceutice care îi conțin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021504388A (ja) * 2017-11-29 2021-02-15 レ ラボラトワール セルヴィエ ユビキチン特異的プロテアーゼ7の阻害剤としての新規ピペリジニル誘導体

Also Published As

Publication number Publication date
MY196562A (en) 2023-04-19
CN109311888A (zh) 2019-02-05
PH12018502515B1 (en) 2021-11-10
CR20180564A (es) 2019-03-04
CN109311888B (zh) 2021-09-14
DK3468974T3 (da) 2020-05-11
MA45222B1 (fr) 2020-04-30
CL2018003474A1 (es) 2019-05-24
TN2018000410A1 (en) 2020-06-15
ES2775789T3 (es) 2020-07-28
LT3468974T (lt) 2020-04-10
UA123794C2 (uk) 2021-06-02
PL3468974T3 (pl) 2020-07-13
RU2018147430A3 (enExample) 2020-07-10
US20190144448A1 (en) 2019-05-16
EP3468974B1 (en) 2020-02-12
GEP20207160B (en) 2020-10-12
AR108706A1 (es) 2018-09-19
CA3027014A1 (en) 2017-12-14
UY37288A (es) 2018-01-02
JP2019517556A (ja) 2019-06-24
HUE049507T2 (hu) 2020-09-28
SV2018005791A (es) 2019-01-16
KR20190016106A (ko) 2019-02-15
US11046681B2 (en) 2021-06-29
RU2018147430A (ru) 2020-07-10
CA3027014C (en) 2021-01-05
TWI620750B (zh) 2018-04-11
IL263463B (en) 2021-01-31
FR3052452B1 (fr) 2018-06-22
FR3052452A1 (enExample) 2017-12-15
MD3468974T2 (ro) 2020-05-31
PT3468974T (pt) 2020-03-25
EP3468974A1 (en) 2019-04-17
SI3468974T1 (sl) 2020-07-31
SG11201810629QA (en) 2018-12-28
PE20220567A1 (es) 2022-04-13
CU20180145A7 (es) 2019-07-04
TW201802092A (zh) 2018-01-16
CO2018013210A2 (es) 2018-12-28
CY1122870T1 (el) 2021-05-05
PH12018502515A1 (en) 2019-09-30
EA201892838A1 (ru) 2019-06-28
ECSP18090144A (es) 2019-01-31
NZ748946A (en) 2025-06-27
MX374794B (es) 2025-03-06
RU2743163C2 (ru) 2021-02-15
HRP20200361T1 (hr) 2020-06-12
IL263463A (en) 2019-01-31
DOP2018000270A (es) 2019-05-15
NI201800132A (es) 2019-04-08
WO2017212012A1 (en) 2017-12-14
MA45222A (fr) 2019-04-17
AU2017277734B2 (en) 2021-07-01
EA037211B1 (ru) 2021-02-19
AU2017277734A1 (en) 2018-12-20
BR112018075433A2 (pt) 2019-03-19
MX2018015216A (es) 2019-04-25
ME03670B (en) 2020-10-20
RS60029B1 (sr) 2020-04-30

Similar Documents

Publication Publication Date Title
JP6928005B2 (ja) 新規なピペリジニル誘導体、それらの調製方法及びそれらを含有する医薬組成物
US11667635B2 (en) Bicyclic heterocycles as FGFR4 inhibitors
US20160115164A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
CA3083320C (en) Piperidinyl derivatives as inhibitors of ubiquitin specific protease 7
HK40007201B (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40007201A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
HK40004049A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
OA19084A (en) New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them.
HK40034164A (en) New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210805

R150 Certificate of patent or registration of utility model

Ref document number: 6928005

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250